Cost utility analysis of the SQ(®) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

BACKGROUND: Asthma affects an estimated 300 million people worldwide with the condition associated with significant healthcare utilisation costs and a large impact on patient quality of life. The SQ(®) HDM SLIT-tablet (ACARIZAX(®), Hørsholm, Denmark) is a sublingually administered allergy immunother...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Transl Allergy
Autors principals: Hahn-Pedersen, J., Worm, M., Green, W., Andreasen, J. Nørgaard, Taylor, M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Brief Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5015209/
https://ncbi.nlm.nih.gov/pubmed/27610217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0127-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars